Date: Nov 01, 2018 Author: Nick Caprioli Source: Company Data (
click here to go to the source)
NASHVILLE, Tenn. -- Frontier Diagnostics announced today a move to a new corporate laboratory and headquarters at 345 Hill Avenue, at the intersection of the Woodbine and Glenview neighborhoods, in Nashville, Tennessee. This new location will provide both laboratory and office space needed as the company continues to work towards meeting the goals outlined in the NIH SBIR Grant awarded in 2018.
"The space at 345 Hill Avenue will allow for us to take our research to the next level as we begin to hire additional people and continue our efforts in Phase 1 of the SBIR Grant," said FrontierDx President and Chief Executive Officer Jeremy Norris. "We are excited for our team to move into the new space and to begin to settle in."
Frontier Diagnostics was founded in 2014 by Dr. Jeremy L. Norris and Dr. Richard M. Caprioli with the goal of leveraging the latest imaging mass spectrometry to revolutionize cancer diagnosis. In 2018, Frontier Diagnostics was awarded an NIH SBIR Grant to continue to research methods of improving pathological cancer diagnosis via these breakthrough technologies. Their first clinical assay, MelanoMapTM, is preparing for commercial launch in 2019.
